BiBo Biopharma

BiBo Biopharma is a global Contract Development and Manufacturing Organization (CDMO) specializing in the full-spectrum CMC lifecycle of biologics. Founded in 2014 in Boston and headquartered in Shanghai, the company is a pioneer in "Fourth Wave" biomanufacturing, utilizing its proprietary PanFlex-Engineering and PanFlex-Operation systems. BiBo is notable for developing the world's first and largest 30,000L and 50,000L stainless steel bioreactors, which aim to significantly reduce production costs for monoclonal antibodies and other large molecules to as low as $10 per gram. The company offers one-stop services from DNA to commercial production across platforms including mammalian cell culture, microbial fermentation, gene therapy, and antibody-drug conjugates (ADCs). BiBo has supported over 130 projects and maintains a strategic partnership with 89bio to manufacture the MASH candidate pegozafermin. With R&D and manufacturing sites in China and the United States, BiBo provides high-quality, affordable large-scale commercial manufacturing to accelerate the success of global biopharmaceutical clients.